HAE

MKT CAP:$3B

Haemonetics Corporation

Market Cap

$3B

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NYSE

Healthcare·Medical·🇺🇸·NYSE

Stock Price

$59.93-$20.05 (-25.07%)

Apr 24, 2026

Company Details

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and...

CEO

Christopher A. Simon

IPO Date

May 10, 1991

Website

www.haemonetics.com

Key Metrics TTM

Revenue

$1.3B

-4.0% YoY

Net Income

$175M

EPS (Diluted)

$3.63

Free Cash Flow

$308M

Revenue / Share

$28.06

Gross Margin

58.5%

Operating Margin

19.2%

Net Margin

13.3%

FCF Margin

23.4%

P/S

2.1x

P/E

15.9x

Earnings Reports

Q4 2026

May 7, 2026

PENDING

Q3 2026

Feb 5, 2026

$339M-2.7%EPS $0.95

Q2 2026

Nov 6, 2025

$327M-5.3%EPS $0.81

Q1 2026

Aug 7, 2025

$321M-4.4%EPS $0.70

FY 2025

May 21, 2025

$1.4B+4.0%EPS $3.31

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 22	$265M	$154M	$19M
Q1 23	$261M	$142M	$31M
Q2 23	$297M	$158M	$47M
Q3 23	$305M	$159M	$43M
Q4 23	$304M	$164M	$35M
Q1 24	$311M	$167M	$54M
Q2 24	$318M	$171M	$35M
Q3 24	$336M	$185M	$46M
Q4 24	$343M	$189M	$30M
Q1 25	$336M	$179M	$40M
Q2 25	$346M	$191M	$52M
Q3 25	$349M	$200M	$59M
Q4 25	$331M	$193M	$71M
Q1 26	$321M	$192M	$54M
Q2 26	$327M	$195M	$58M
Q3 26	$339M	$191M	$70M

Valuation

Quarter	P/S	P/E
Q4 22	2.8x	64.3x
Q1 23	2.7x	41.2x
Q2 23	2.6x	32.4x
Q3 23	2.5x	29.1x
Q4 23	2.4x	24.2x
Q1 24	2.3x	20.4x
Q2 24	2.3x	21.7x
Q3 24	2.2x	22.0x
Q4 24	2.1x	23.7x
Q1 25	2.1x	24.3x
Q2 25	2.0x	22.5x
Q3 25	2.0x	21.4x
Q4 25	2.1x	16.6x
Q1 26	2.1x	17.1x
Q2 26	2.1x	16.6x
Q3 26	2.1x	15.9x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	$68M	$33M
Q1 23	$42M	-$3M
Q2 23	$87M	$51M
Q3 23	$64M	$48M
Q4 23	$80M	$68M
Q1 24	$19M	$9M
Q2 24	$99M	$74M
Q3 24	-$540.0K	-$15M
Q4 24	$64M	$54M
Q1 25	-$27M	-$33M
Q2 25	$49M	$39M
Q3 25	$44M	$35M
Q4 25	$117M	$101M
Q1 26	$17M	$14M
Q2 26	$111M	$106M
Q3 26	$94M	$87M

Capital Expenditures

Quarter	CapEx
Q4 22	$35M
Q1 23	$45M
Q2 23	$36M
Q3 23	$17M
Q4 23	$12M
Q1 24	$10M
Q2 24	$25M
Q3 24	$15M
Q4 24	$10M
Q1 25	$6M
Q2 25	$9M
Q3 25	$9M
Q4 25	$16M
Q1 26	$4M
Q2 26	$5M
Q3 26	$6M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	+17.8%	-0.2%
Q1 23	+14.4%	+1.6%
Q2 23	+24.0%	+16.4%
Q3 23	+17.5%	+16.9%
Q4 23	+14.9%	+9.5%
Q1 24	+19.1%	+11.7%
Q2 24	+7.0%	+12.8%
Q3 24	+10.1%	+10.8%
Q4 24	+12.8%	+16.4%
Q1 25	+8.0%	+15.0%
Q2 25	+8.6%	+3.9%
Q3 25	+3.7%	-0.3%
Q4 25	-3.7%	-17.3%
Q1 26	-4.4%	-9.7%
Q2 26	-5.3%	-8.5%
Q3 26	-2.7%	-6.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$5M	1.9%
Q1 23	$5M	2.0%
Q2 23	$6M	1.9%
Q3 23	$7M	2.5%
Q4 23	$7M	2.3%
Q1 24	$7M	2.2%
Q2 24	$7M	2.1%
Q3 24	$7M	2.1%
Q4 24	$0	0.0%
Q1 25	$0	0.0%
Q2 25	$7M	2.0%
Q3 25	$0	0.0%
Q4 25	$7M	2.1%
Q1 26	$9M	2.9%
Q2 26	$8M	2.3%
Q3 26	$8M	2.3%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$22M	$92M	$4M	—
Q1 23	$11M	—	—	—
Q2 23	$11M	—	—	—
Q3 23	$13M	—	—	—
Q4 23	$24M	$88M	$7M	—
Q1 24	$13M	—	—	—
Q2 24	$13M	—	—	—
Q3 24	$13M	—	—	—
Q4 24	$24M	$108M	$7M	—
Q1 25	$14M	—	—	—
Q2 25	$14M	—	—	—
Q3 25	$16M	—	—	—
Q4 25	$16M	—	—	$115M
Q1 26	$16M	—	—	—
Q2 26	$15M	—	—	$102M
Q3 26	$14M	—	—	$108M

Revenue Segments

Quarter	Blood Center	Hospital	Plasma
Q1 23	$67M	$89M	$103M
Q2 23	$76M	$93M	$129M
Q3 23	$77M	$94M	$137M
Q1 24	$67M	$100M	$139M
Q2 24	$69M	$103M	$142M
Q3 24	$72M	$114M	$147M
Q1 25	$67M	$134M	$136M
Q2 25	$69M	$138M	$139M
Q3 25	$71M	$144M	$134M
Q1 26	$52M	$140M	$130M

Revenue by Geography

Quarter	Asia	Europe	Japan	Other Country or Region	United States
Q1 23	$24M	$40M	$14M	$703.0K	$182M
Q2 23	$28M	$42M	$15M	$921.0K	$212M
Q3 23	$25M	$39M	$16M	$1M	$224M
Q1 24	$22M	$39M	$12M	$1M	$237M
Q2 24	$28M	$39M	$15M	$426.0K	$236M
Q3 24	$31M	$37M	$15M	$3M	$251M
Q1 25	$20M	$47M	$14M	$7M	$249M
Q2 25	$26M	$42M	$16M	$5M	$256M
Q3 25	$26M	$44M	$16M	$5M	$258M
Q1 26	$22M	$41M	$14M	$3M	$242M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$259M	$0	$259M
Q1 23	$215M	$0	$215M
Q2 23	$241M	$0	$241M
Q3 23	$224M	$0	$224M
Q4 23	$284M	$0	$284M
Q1 24	$286M	$0	$286M
Q2 24	$351M	$0	$351M
Q3 24	$194M	$0	$194M
Q4 24	$179M	$0	$179M
Q1 25	$344M	$0	$344M
Q2 25	$299M	$0	$299M
Q3 25	$321M	$0	$321M
Q4 25	$307M	$0	$307M
Q1 26	$293M	$0	$293M
Q2 26	$296M	$0	$296M
Q3 26	$363M	$0	$363M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 22	51M	+0.0%	+1.0%
Q1 23	52M	+0.6%	+1.5%
Q2 23	52M	-0.2%	+0.2%
Q3 23	51M	-0.7%	-0.2%
Q4 23	51M	+0.0%	-0.3%
Q1 24	51M	+0.2%	-0.7%
Q2 24	51M	+0.1%	-0.3%
Q3 24	51M	+0.1%	+0.4%
Q4 24	51M	-0.1%	+0.4%
Q1 25	52M	+0.3%	+0.4%
Q2 25	51M	-0.6%	-0.3%
Q3 25	51M	-1.2%	-1.6%
Q4 25	49M	-2.3%	-3.8%
Q1 26	48M	-2.3%	-6.2%
Q2 26	48M	-1.4%	-7.0%
Q3 26	47M	-1.4%	-7.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 22	$82.2K	3K
Q1 23	$81.1K	3K
Q2 23	$92.2K	3K
Q3 23	$94.7K	3K
Q4 23	$94.4K	3K
Q1 24	$96.5K	3K
Q2 24	$98.7K	3K
Q3 24	$104.3K	3K
Q4 24	$106.4K	3K
Q1 25	$104.2K	3K
Q2 25	$107.1K	3K
Q3 25	$108.1K	3K
Q4 25	$102.5K	3K
Q1 26	$99.7K	3K
Q2 26	$101.5K	3K
Q3 26	$105.1K	3K

Revenue / Employee